Compare Wayfair Inc (W) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wayfair Inc vs GeneDx Holdings Corp — how do they compare? Wayfair Inc trades at $105.8 (market cap $14.40B), while GeneDx Holdings Corp trades at $67.92 (market cap $2.02B). The key difference: Wayfair Inc is far larger — about 7.1× GeneDx Holdings Corp's market cap, and Wayfair Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Wayfair Inc for 8 Days and GeneDx Holdings Corp for 19 Days on average.
| W | WGS | |
|---|---|---|
Market Cap | $14.40B | $2.02B |
Volume | 2,102,856 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $119.05 | $167.51 |
52-Week Low | $57.40 | $34.51 |
Typical Hold Time | 8 Days | 19 Days |
Enterprise Value | $16.73B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wayfair (W) trades at $105.70, up 1.18% today, with a bullish technical signal and strong analyst support. The stock shows positive earnings surprises in recent quarters, though it remains unprofitable with a net income margin of -2.49%. Revenue growth is modest, and the company maintains a solid gross profit margin of 30.05%. Recent news highlights brand expansion and upcoming Q3 2026 earnings.
The outlook is cautiously optimistic with a consensus price target of $114.13, implying upside potential. Key risks include persistent losses, high debt-to-asset ratio, and competitive pressures. Investor sentiment is positive, but profitability challenges and macroeconomic headwinds warrant careful monitoring for sustained growth.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
